{
    "root": "9e588c43-b9b5-478e-99f7-e197add3cd26",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Levothyroxine Sodium",
    "value": "20250401",
    "ingredients": [
        {
            "name": "D&C RED NO. 27",
            "code": "2LRS185U6K"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "D&C RED NO. 30",
            "code": "2S42T2808B"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "LEVOTHYROXINE SODIUM",
            "code": "9J765S329G",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00451"
        }
    ],
    "indications": {
        "text": "hypothyroidism levothyroxine sodium tablets indicated replacement therapy primary ( thyroidal ) , secondary ( pituitary ) tertiary ( hypothalamic ) congenital acquired hypothyroidism . pituitary thyrotropin ( thyroid-stimulating hormone , tsh ) suppression levothyroxine sodium tablets indicated adjunct surgery radioiodine therapy management thyrotropin-dependent well-differentiated thyroid cancer . limitations : \u2022 levothyroxine sodium tablets indicated suppression benign thyroid nodules nontoxic diffuse goiter iodine-sufficient patients benefits overtreatment levothyroxine sodium tablets may induce hyperthyroidism [ ( 5.4 ) ] . \u2022 levothyroxine sodium tablets indicated treatment hypothyroidism recovery phase subacute thyroiditis .",
        "doid_entities": [
            {
                "text": "hypothyroidism (DOID:1459)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1459"
            },
            {
                "text": "thyroid cancer (DOID:1781)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1781"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "goiter (DOID:12176)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12176"
            },
            {
                "text": "hyperthyroidism (DOID:7998)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7998"
            },
            {
                "text": "subacute thyroiditis (DOID:7165)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7165"
            },
            {
                "text": "thyroiditis (DOID:7166)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7166"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 administer daily , preferably empty stomach , one-half one hour breakfast . ( 2.1 ) \u2022 administer least 4 hours drugs known interfere absorption . ( 2.1 ) \u2022 evaluate need dose adjustments regularly administering within one hour certain foods may affect absorption . ( 2.1 ) \u2022 starting dose depends variety factors , including age , body weight , cardiovascular status concomitant medications . peak therapeutic effect may attained 4-6 weeks . ( 2.2 ) \u2022 full prescribing information dosing patient . ( 2.3 ) \u2022 adequacy therapy determined periodic monitoring tsh and/or t4 well status . ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "levothyroxine sodium tablets , usp supplied follows : strength ( mcg ) color/shape tablet markings ndc # bottles 90 100 yellow/ caplet `` 100 `` `` gg/335 `` 82804-222-90",
    "adverseReactions": "levothyroxine sodium tablets contraindicated patients uncorrected adrenal insufficiency [ ( 5.3 ) ] .",
    "indications_original": "Hypothyroidism\n                  \n                  Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism.\n                  \n                     Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression\n                  \n                  Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.\n                  \n                     Limitations of Use:\n                      \u2022 Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)].  \n                  \u2022 Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.",
    "contraindications_original": "\u2022 Administer once daily, preferably on an empty stomach, one-half to one hour before breakfast. (2.1) \u2022 Administer at least 4 hours before or after drugs that are known to interfere with absorption. (2.1) \u2022 Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. (2.1) \u2022 Starting dose depends on a variety of factors, including age, body weight, cardiovascular status and concomitant medications. Peak therapeutic effect may not be attained for 4-6 weeks. (2.2) \u2022 See full prescribing information for dosing in specific patient populations. (2.3) \u2022 Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status. (2.4)",
    "warningsAndPrecautions_original": "Levothyroxine Sodium Tablets, USP are supplied as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              Strength (mcg)\n                           \n                           \n                              Color/Shape\n                           \n                           \n                              Tablet Markings\n                           \n                           \n                              NDC# for bottles of 90\n                           \n                        \n                     \n                     \n                        \n                           \n                              100\n                           \n                           \n                              Yellow/ Caplet\n                           \n                           \n                              \"100\" and \"GG/335\"\n                           \n                           \n                              82804-222-90",
    "adverseReactions_original": "Levothyroxine sodium tablets is contraindicated in patients with uncorrected adrenal insufficiency     [see Warnings and Precautions (5.3)] .",
    "drug": [
        {
            "name": "Levothyroxine Sodium",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00451"
        }
    ]
}